{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:52:52Z","timestamp":1789404772811,"version":"build-2803163510"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Prostate cancer is the most frequently diagnosed malignancy and the second\u2010leading cause of cancer death in men. The purpose of this study was to determine the anti\u2010proliferative and anti\u2010angiogenic efficacy of angiotensin\u2010(1\u20107) [Ang\u2010(1\u20107)], an endogenous peptide hormone, in human prostate cancer xenografts.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Human LNCaP prostate cancer cells were injected into the flank of athymic mice and tumors were treated with Ang\u2010(1\u20107) for 54 days. Tumor growth and angiogenesis were determined by immunohistochemistry and western blot hybridization.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Ang\u2010(1\u20107) markedly reduced the volume and wet weight of LNCaP xenograft tumors. Histological analysis of tumor sections from saline\u2010treated mice showed increased Ki67 immunoreactivity and enhanced phosphorylation of the MAP kinases ERK1\/2 compared to tumors from Ang\u2010(1\u20107)\u2010treated mice, suggesting that the heptapeptide reduces cell proliferation. Intratumoral vessel density was decreased in Ang\u2010(1\u20107)\u2010treated mice with an associated reduction in vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), suggesting that the heptapeptide attenuates vascularization by reducing angiogenic factors. Ang\u2010(1\u20107) administration markedly increased the soluble fraction of VEGF receptor 1 (sFlt\u20101), with a concomitant reduction in VEGF receptors 1 and 2. sFlt\u20101 serves as a decoy receptor that traps VEGF and PlGF, making the ligands unavailable to membrane\u2010bound VEGF receptors and preventing activation of pro\u2010angiogenic signaling.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The decrease in PlGF and VEGF coupled with the increase in sFlt\u20101 suggests that Ang\u2010(1\u20107) may serve as a novel anti\u2010angiogenic therapy for prostate cancer. Further, the pleiotropic mechanisms of action by Ang\u2010(1\u20107) may limit angiogenic resistance that occurs with VEGF inhibitors or receptor blockers. Prostate 73: 60\u201370, 2013. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.22540","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T17:47:24Z","timestamp":1338313644000},"page":"60-70","source":"Crossref","is-referenced-by-count":61,"title":["Angiotensin\u2010(1\u20107) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt\u20101"],"prefix":"10.1002","volume":"73","author":[{"given":"Bhavani","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia E.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ann","family":"Tallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,29]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"479","volume-title":"The handbook of biologically active peptides","author":"Tallant EA","year":"2006"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-008-0340-4"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.01981.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.74"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.02.090"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2945"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn171"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.21"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2009.184"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20407"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01937.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21312"},{"key":"e_1_2_6_14_2","first-page":"1139","article-title":"Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor","volume":"2","author":"Uemura H","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.08.032"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2174\/156800911795538101"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03228-0"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.31.1.362"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.3.535"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00941.2004"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh236"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3614"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1136"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00562-7"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.280.4.R994"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0161"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1957"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20181"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00666038"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.01.006"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.08.038"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25026"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.22.10705"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-26"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013847.07035.B9"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.1.207"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0078-4"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2009.11.011"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00423-8"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.21579"},{"key":"e_1_2_6_41_2","first-page":"3767","article-title":"Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia","volume":"23","author":"Matsumoto K","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.051041"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0461"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2524"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.02.007"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp111"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.28.1.104"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.020"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2009.12.001"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172398299"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.12.14009"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1726-4901(10)70097-6"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.22540","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.22540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:37:08Z","timestamp":1698640628000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.22540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,29]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/pros.22540"],"URL":"https:\/\/doi.org\/10.1002\/pros.22540","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,29]]}}}